Osteoarthritis of the knee is a progressing degenerative joint disorder, characterised by joint pain and limitation of movement, leading to disability. Tissue changes comprise damage of joint cartilage, synovial inflammation and changes in subchondral bone, such as subchondral sclerosis and osteophyte formation (bony outgrowths).
Conditions
Interventions
Celecoxib: 4 weeks, 2 times per day, 200 mg
Naproxen: 4 weeks, 3 times per day, 250 mg
Indomethacin: 4 weeks, 2 times per day, 50 mg.
Sponsors
UMC Utrecht
Rheumatology & Clin. Immunology
Eligibility
Inclusion criteria
Inclusion criteria: Patients with knee osteoarthritis according to the ACR criteria, considered for total knee replacement surgery.
Exclusion criteria
Exclusion criteria: 1. Total knee replacement for other reason than osteoarthritis; 2. History of gastro-intestinal bleedings or perforation; 3. Increased risk for cardiovascular diseases (cardiovascular diseases in history, patients with untreated hypertension, patients with angina pectoris, and patients on oral anticoagulantia).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Difference in proteoglycan release of osteoarthritic cartilage after treatment. | — |
Secondary
| Measure | Time frame |
|---|---|
| ProsteoglandinE2 levels produced by cartilage. | — |
Contacts
Public ContactA.C.A. Marijnissen
University Medical Center Utrecht (UMCU), Department of Rheumatology and Clinical Immunology, F02.127, P.O. Box 85500
Outcome results
None listed